{"entity":{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","aka":[],"tldr":"Karyopharm makes selinexor, the first nuclear export inhibitor, approved in myeloma; its endometrial cancer bet failed in 2026.","summary":"Karyopharm Therapeutics, based in Newton, Massachusetts, and listed as KPTI, makes selinexor, sold as Xpovio, the first nuclear export inhibitor, approved in multiple myeloma and diffuse large B-cell lymphoma. Its bet on endometrial cancer failed in 2026 when the phase 3 XPORT-EC-042 trial of maintenance selinexor in TP53-wild-type disease missed its primary endpoint in July, after which the company refocused on myelofibrosis and myeloma. OnCo links it to endometrial cancer, to the XPORT-EC-042 trial record and to selinexor. Whether a biomarker-selected maintenance strategy failed because of the drug or because of the TP53 hypothesis is the question the trial leaves open. Selinexor has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.karyopharm.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["selinexor"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04442022","nct02227251","nct02343042","nct04414475","nct04562389"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Newton, MA","country":"US","companyType":"biotech","website":"https://www.karyopharm.com","ticker":"KPTI","investors":[],"funding":[]},"route":"/companies/karyopharm/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"}],"trial":[{"id":"nct04442022","kind":"trial","name":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly","route":"/trials/nct04442022/"},{"id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/"},{"id":"nct02227251","kind":"trial","name":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","route":"/trials/nct02227251/"},{"id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/"},{"id":"nct04562389","kind":"trial","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","route":"/trials/nct04562389/"},{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/"}],"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}]}}